PTGX
HEALTHCAREProtagonist Therapeutics Inc
$103.97+4.76 (+4.80%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PTGX Today?
No stock-specific AI insight has been generated for PTGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$42.85$107.84
$103.97
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS$-1.81
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-1.5%
Debt / Equity—
Trading
Volume990K
Avg Volume (10D)—
Shares Outstanding64.3M
PTGX News
21 articles- Protagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS ForecastsYahoo Finance·May 8, 2026
- Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?Yahoo Finance·May 7, 2026
- Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This StockYahoo Finance·May 2, 2026
- Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda CollaborationYahoo Finance·Apr 28, 2026
- Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This StockYahoo Finance·Apr 27, 2026
- High Growth Tech Stocks To Watch In US April 2026Yahoo Finance·Apr 24, 2026
- Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsightGlobeNewswire Inc.·Apr 22, 2026
- How to Play J&J Stock Post a Beat-and-Raise Performance in Q1Yahoo Finance·Apr 20, 2026
- Protagonist Therapeutics Reports Granting of Inducement AwardsYahoo Finance·Apr 16, 2026
- Growth vs. Stability: Lilly and J&J's 2026 Investment Face-OffYahoo Finance·Apr 13, 2026
- Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price SurgeYahoo Finance·Apr 4, 2026
- Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV TreatmentYahoo Finance·Apr 3, 2026
- This Healthcare Stock Barely Flinches During Market Sell-OffsThe Motley Fool·Apr 2, 2026
- Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual MeetingYahoo Finance·Mar 28, 2026
- Do Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential?Yahoo Finance·Mar 27, 2026
- Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?Yahoo Finance·Mar 27, 2026
- J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026Yahoo Finance·Mar 26, 2026
- US High Growth Tech Stocks to Watch NowYahoo Finance·Mar 25, 2026
- Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition TargetsYahoo Finance·Mar 25, 2026
- J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?Yahoo Finance·Mar 24, 2026
All 21 articles loaded
Price Data
Open$0.00
Previous Close$99.21
Day High$0.00
Day Low$0.00
52 Week High$107.84
52 Week Low$42.85
52-Week Range
$42.85$107.84
$103.97
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS$-1.81
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin-1.5%
Debt / Equity—
Trading
Volume990K
Avg Volume (10D)—
Shares Outstanding64.3M
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—